- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Elevated Circulating FFA and Intrahepatic Lipid Content (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=34, Completed, Recruiting --> Completed | N=12 --> 34 | Trial primary completion date: Dec 2013 --> Jun 2013
- |||||||||| Trial completion, Trial primary completion date, HEOR: Quality of Life After Liver Resection (clinicaltrials.gov) - Nov 15, 2015
P=N/A, N=198, Completed, Recruiting --> Completed | N=12 --> 34 | Trial primary completion date: Dec 2013 --> Jun 2013 Active, not recruiting --> Completed | Trial primary completion date: Jan 2013 --> Jan 2014
- |||||||||| Biomarker, Trial completion, Trial primary completion date: Alcohol Biomarkers in Post-Liver Transplant Patients (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=214, Completed, Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Oct 2015
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C (clinicaltrials.gov) - Nov 9, 2015
P2, N=37, Completed, N=160 --> 45 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Jan 2015; The trial was terminated due to change in new standard of therapy during the study period. Recruiting --> Completed | N=70 --> 37 | Trial primary completion date: Apr 2016 --> Nov 2015
- |||||||||| oprozomib (ONX 0912) / Amgen
Enrollment change, Trial withdrawal, Trial primary completion date, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 6, 2015 P1/2, N=0, Withdrawn, Recruiting --> Active, not recruiting N=140 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Apr 2017 --> Mar 2015
- |||||||||| emricasan (IDN 6556) / Histogen, Amerimmune
Trial primary completion date: A Study of IDN-6556 in Subjects With Liver Cirrhosis (clinicaltrials.gov) - Nov 3, 2015 P2, N=80, Active, not recruiting, Enrolling by invitation --> Active, not recruiting Trial primary completion date: Sep 2015 --> Jan 2016
- |||||||||| Trial completion: Sarcopenia and Cirrhosis (clinicaltrials.gov) - Oct 30, 2015
P=N/A, N=17, Completed, Initiation date: Oct 2013 --> Jun 2013 Recruiting --> Completed
- |||||||||| albumin-bound paclitaxel / Generic mfg.
Trial primary completion date, Metastases: Hepatic Arterial Infusion (HAI) of Abraxane (clinicaltrials.gov) - Oct 29, 2015 P1, N=56, Active, not recruiting, Recruiting --> Completed Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| Enrollment change, Trial termination: A Health Intervention to Prevent Depression Hepatitis C Patients (clinicaltrials.gov) - Oct 27, 2015
P2/3, N=1, Terminated, Trial primary completion date: Jun 2015 --> Jun 2016 N=50 --> 1 | Recruiting --> Terminated; Lack of eligible patients due to introduction of new drugs for Hepatitis C
- |||||||||| Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Combination therapy: Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Na (clinicaltrials.gov) - Oct 26, 2015 P3, N=74, Completed, Trial primary completion date: Jun 2015 --> Nov 2015 Active, not recruiting --> Completed
- |||||||||| Trial primary completion date: Sarcopenia and Cirrhosis (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=20, Recruiting, Active, not recruiting --> Completed Trial primary completion date: Jan 2015 --> Dec 2015
- |||||||||| Biomarker, Trial primary completion date: Nonalcoholic Fatty Liver Disease in Taiwanese Children (clinicaltrials.gov) - Oct 23, 2015
P=N/A, N=800, Recruiting, Trial primary completion date: Jan 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Dec 2017
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF) (clinicaltrials.gov) - Oct 22, 2015
P2, N=8, Terminated, Not yet recruiting --> Recruiting | N=53 --> 29 | Trial primary completion date: Apr 2019 --> Dec 2016 N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Due to VTI-208 results, the ELAD clinical plan is being re-evaluated.
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure (clinicaltrials.gov) - Oct 22, 2015
P3, N=18, Terminated, N=40 --> 8 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Sep 2015; Due to VTI-208 results, the ELAD clinical plan is being re-evaluated. N=150 --> 18 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Due to results from the VTI-208 study, the ELAD plan is being re-evaluated.
- |||||||||| pimasertib (AS703026) / Day One Biopharma
Enrollment change, Trial termination, Trial primary completion date, Monotherapy: EMR 200066-010: A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy (clinicaltrials.gov) - Oct 22, 2015 P1, N=26, Terminated, N=150 --> 18 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Due to results from the VTI-208 study, the ELAD plan is being re-evaluated. N=80 --> 26 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Apr 2015; The sponsor decided not to conduct the expansion part of trial (part 2)
- |||||||||| L-ornithine-L-aspartate / Generic mfg.
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate (clinicaltrials.gov) - Oct 22, 2015 P4, N=42, Completed, N=80 --> 26 | Recruiting --> Terminated | Trial primary completion date: Nov 2015 --> Apr 2015; The sponsor decided not to conduct the expansion part of trial (part 2) Not yet recruiting --> Completed | N=34 --> 42 | Initiation date: May 2013 --> Aug 2013 | Trial primary completion date: Oct 2014 --> Jun 2015
|